A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153

Summary

RV6153 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The main purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of RV6153

Timeline

Start

2015-07

Primary completion

2016-02

Completion

2016-02

Outcome

Outcome not reported

Stopped: “Preset pharmacokinetic stopping criteria met at lower doses than expected.”

Drugs

Indications